MX2016016744A - Inhibidores de ezh2 para tratar linfomas. - Google Patents

Inhibidores de ezh2 para tratar linfomas.

Info

Publication number
MX2016016744A
MX2016016744A MX2016016744A MX2016016744A MX2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A MX 2016016744 A MX2016016744 A MX 2016016744A
Authority
MX
Mexico
Prior art keywords
ezh2 inhibitors
ezh2
treating lymphoma
subject
present
Prior art date
Application number
MX2016016744A
Other languages
English (en)
Inventor
Keilhack Heike
Ottesen Lone
Reyderman Larisa
K Knutson Sarah
Danielle Johnston L
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2016016744A publication Critical patent/MX2016016744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se refiere a métodos para tratar el cáncer mediante la administración de un inhibidor de EZH2 o de una composición farmacéutica del mismo al sujeto que lo necesite. Las presentes reivindicaciones definen métodos para tratar subtipos específicos de linfoma no Hodgkin que comprenden la administración a un sujeto de inhibidores de EZH2. Los inhibidores de EZH2 preferidos incluyen tazemetostat (EPZ6438 E7438) y otros compuestos. También se definen cantidades y regímenes de dosificación.
MX2016016744A 2014-06-17 2015-06-17 Inhibidores de ezh2 para tratar linfomas. MX2016016744A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013522P 2014-06-17 2014-06-17
US201462036265P 2014-08-12 2014-08-12
PCT/US2015/036310 WO2015195848A1 (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma

Publications (1)

Publication Number Publication Date
MX2016016744A true MX2016016744A (es) 2017-11-30

Family

ID=54936086

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016016744A MX2016016744A (es) 2014-06-17 2015-06-17 Inhibidores de ezh2 para tratar linfomas.
MX2021007651A MX2021007651A (es) 2014-06-17 2015-06-17 Inhibidores de ezh2 para tratar linfomas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007651A MX2021007651A (es) 2014-06-17 2015-06-17 Inhibidores de ezh2 para tratar linfomas.

Country Status (21)

Country Link
US (5) US10166238B2 (es)
EP (2) EP4252851A3 (es)
JP (1) JP6779793B2 (es)
KR (2) KR20230031963A (es)
CN (2) CN113289022A (es)
AU (3) AU2015277139A1 (es)
BR (1) BR112016029492A2 (es)
CA (1) CA2952074C (es)
DK (1) DK3157527T3 (es)
EA (1) EA038337B1 (es)
ES (1) ES2948442T3 (es)
FI (1) FI3157527T3 (es)
HU (1) HUE062158T2 (es)
IL (3) IL309539A (es)
LT (1) LT3157527T (es)
MX (2) MX2016016744A (es)
PL (1) PL3157527T3 (es)
PT (1) PT3157527T (es)
SG (2) SG11201610273VA (es)
SI (1) SI3157527T1 (es)
WO (1) WO2015195848A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US20160303135A1 (en) 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) * 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
BR112017007738B1 (pt) 2014-10-16 2023-04-11 Epizyme, Inc Método para determinar a probabilidade de eficácia de um tratamento e método para triagem da eficácia de um tratamento compreendendo um inibidor de ezh2
CN116650500A (zh) * 2014-11-17 2023-08-29 Epizyme股份有限公司 治疗癌症的方法
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
JP2018513865A (ja) 2015-04-20 2018-05-31 エピザイム，インコーポレイティド 癌を処置するための併用療法
CA2988816A1 (en) * 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
AU2018210141A1 (en) * 2017-01-20 2019-08-29 Constellation Pharmaceuticals, Inc. Solid dispersions of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
US20210161883A1 (en) * 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
KR102061353B1 (ko) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CN103987842A (zh) 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
EP2825161B1 (en) * 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
LT3184523T (lt) 2012-04-13 2020-02-10 Epizyme Inc N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
CN104768555B (zh) 2012-04-13 2018-10-30 Epizyme股份有限公司 用于治疗癌症的联合治疗
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
TWI588131B (zh) 2012-10-15 2017-06-21 雅酶股份有限公司 經取代苯化合物
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
ES2691742T5 (es) 2012-11-01 2022-03-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US20160113932A1 (en) 2013-05-30 2016-04-28 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
CA2923706C (en) 2013-10-09 2020-08-25 F. Hoffmann-La Roche Ag Methods and compositions for detecting mutation in the human ezh2 gene
PL3057962T3 (pl) 2013-10-16 2024-01-29 Epizyme, Inc. Postać soli chlorowodorku do inhibicji ezh2
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
US20160303135A1 (en) 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) * 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
KR20170098808A (ko) 2014-11-06 2017-08-30 다나-파버 캔서 인스티튜트 인크. 이식편 대 숙주 질환 (gvhd)에 대한 염색질 구조를 조정하는 조성물의 용도
CN116650500A (zh) 2014-11-17 2023-08-29 Epizyme股份有限公司 治疗癌症的方法
JP6544507B2 (ja) 2015-02-09 2019-07-17 日本精機株式会社 ヘッドアップディスプレイ装置
CA2988816A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
KR20170095656A (ko) 2016-02-15 2017-08-23 동부대우전자 주식회사 방열구조를 갖는 세탁기

Also Published As

Publication number Publication date
US20240058348A1 (en) 2024-02-22
EP4252851A3 (en) 2023-11-22
EA038337B1 (ru) 2021-08-11
WO2015195848A1 (en) 2015-12-23
IL285201B1 (en) 2024-01-01
WO2015195848A8 (en) 2016-07-07
US20200022987A1 (en) 2020-01-23
PT3157527T (pt) 2023-06-30
CN106999498A (zh) 2017-08-01
AU2020244382B2 (en) 2022-08-04
KR20170052558A (ko) 2017-05-12
BR112016029492A2 (pt) 2017-10-17
DK3157527T3 (da) 2023-07-03
SG10201811128RA (en) 2019-01-30
AU2015277139A1 (en) 2016-12-22
EP3157527B1 (en) 2023-05-24
ES2948442T3 (es) 2023-09-12
CN106999498B (zh) 2021-06-08
EA201692285A8 (ru) 2018-01-31
FI3157527T3 (fi) 2023-07-25
CA2952074C (en) 2022-08-30
CA2952074A1 (en) 2015-12-23
IL285201A (en) 2021-08-31
US20170216300A1 (en) 2017-08-03
KR20230031963A (ko) 2023-03-07
HUE062158T2 (hu) 2023-10-28
US20190175604A1 (en) 2019-06-13
IL309539A (en) 2024-02-01
EA201692285A1 (ru) 2017-06-30
IL249438A0 (en) 2017-02-28
KR102497728B1 (ko) 2023-02-09
JP2017518334A (ja) 2017-07-06
NZ727108A (en) 2023-09-29
EP3157527A1 (en) 2017-04-26
JP6779793B2 (ja) 2020-11-04
AU2022263523A1 (en) 2022-12-08
SG11201610273VA (en) 2017-01-27
CN113289022A (zh) 2021-08-24
EP3157527A4 (en) 2018-05-23
PL3157527T3 (pl) 2023-08-07
SI3157527T1 (sl) 2023-09-29
US11642347B2 (en) 2023-05-09
AU2020244382A1 (en) 2020-10-29
MX2021007651A (es) 2021-08-11
US20200323866A1 (en) 2020-10-15
EP4252851A2 (en) 2023-10-04
US10166238B2 (en) 2019-01-01
LT3157527T (lt) 2023-07-25

Similar Documents

Publication Publication Date Title
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12018500642A1 (en) Anti-garp antibody
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016502355A1 (en) Pharmaceutical composition
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PH12016502352A1 (en) Pharmaceutical composition
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TW201613578A (en) Pharmaceutical combinations
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
WO2019039937A8 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER